INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC) is considered to be a therapeutic challenge and a public health issue. Indeed, while ICC incidence is increasing in all western countries [1] , complete surgical resection is currently the only available curative treatment. After surgery, the 5-year survival rate of patients with ICC remains low ranging between 25% and 35% in most of series [2, 3] . This poor prognosis is related to the high recurrence rate, especially during the first year after liver resection. Recently, we showed that ICC recurrences occurred in about half of the patients after surgery with curative intent, frequently during the first year and usually in the remnant liver only [4] . This major early recurrence rate as well as the high rate of patients diagnosed with satellite nodes in both lobes, suggests that ICC is a disseminating parenchymal liver disease. The genomics and molecular mechanisms involved in the onset and progression of ICC are poorly documented. Many arguments based on both experimental data and the expression of specific markers indicated that ICC may originate from cancer stems cells (CSC) or hepatic progenitor cells (HPC) [5] . CSC share functional characteristics with normal stem cells including the potential of self-renewal and pluripotency. Several reports argue about the role of CSC in tumor progression, tumor relapse after treatment and resistance to chemotherapy. Accordingly, Sia et al. demonstrated in a genome wide analysis that their subgroup of progressive ICC was associated with a stem-like ICC signature [6] . Recently, by combining laser capture microdissection and gene expression profiling, a gene signature of the tumor stroma (TS) in ICC have been established and associated with a clinical relevance on prognosis [7] . This genomic signature included 1,073 non-redundant genes that significantly discriminate the TS from non-tumor fibrous tissue.
Interestingly, the most up-regulated genes in the TS included EpCAM, a well-known marker of CSCs in liver tumors [8] . 6 To date, the precise functions of CSC in liver tumors remain poorly understood, particularly due to the lack of accurate cell surface markers that can be isolated on CSC. However, Ma YC et al. showed that the presence of CSCs was associated with a poor histopathologic grade and a worse survival including disease-free survival (DFS) in hepatocellular carcinoma (HCC) [9] .
The aim of the study was to determine whether the expression of CSC markers could predict recurrence following surgical resection of ICC.
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METHODS
Patient Characteristics and Tissue Samples
Forty patients who underwent liver resection with curative intent for ICC at RennesUniversity hospital between Jan; 1997 and Aug. 2011 were studied. Only mass-forming type ICC, as defined by the Liver Cancer Study Group of Japan, were included and analyzed. 
Data Mining of ICC RNA Profiles
RNA analysis was made by using the gene expression profiles that we established previously from the micro dissected stroma of human ICC or fibrous tissue in the adjacent non-tumor liver tissue [10] . The full expression dataset was downloaded from the gene expression omnibus (GEO) database (accession number, GSE45001). Gene set enrichment analysis (GSEA) was performed by using the Java-tool developed at the Broad Institute (Cambridge, MA, USA) as previously described [11] . 
Tissue Microarray Construction (TMA)
To reduce the experimental variations and to standardize the results, immunohistochemistry (IHC) was made by tissue microarray (TMA). TMA design and construction were performed using TMADesigner® software and a Minicore 3® tissue Arrayer (Excilone, VICQ France) as previously described [10] . Briefly, after a hematoxylin-eosin staining, 3 representative areas of stroma from each ICC (TS) and of fibrous tissue from portal tracts areas in the surrounding non tumor liver (NFT) were selected by an experienced pathologist (BT) and were punched with a cylinder of 1mm diameter before transferred to a TMA block. Thus, each tissue block (T and NT) was represented by three independent spots in the TMA.
Subsequently, immunohistochemical studies were performed on 4 µm tissue sections of TMAs.
Immunostaining for EpCAM, CD44 and CD133
IHC was performed for CSC markers (EpCAM, CD44 and CD133). As described previously, 4 µm tissue sections of the TMAs were deparaffinised and immunostained using an in a blind manner. Staining intensity in the stroma was scored as follows: negative (0), mild (1), moderate (2), or strong (3) . Given that each stromal sample was represented in triplicate, the sum of the three values was calculated to obtain a score ranging from 0 to 9. This score 9 was finally categorized into 4 groups to optimize the statistical analysis and to be expandable for: 0 (score 0-1), 1 (score 2-3), 2 (score 4-7) and 3 (score 8-9).
Statistical Analysis
Differences in protein expression TS vs. NFT were evaluated by chi-squared test.
Relationships between protein expression and clinical parameters were evaluated by chisquared or Fisher's exact probability test for categorical variables and using the analysis of variance for numerical variables. The Kaplan-Meier method was used to estimate the overall (OS) and disease-free survival (DFS) and group differences were analyzed with the log-rank test. Univariate and multivariate Cox regression models for the hazards of OS and DFS mortality were used to evaluate the effect of protein expression. The most suited Cox model was selected using a stepwise regression, selecting variables based on the AIC. P<0.05 was considered statistically significant. Statistical analysis was performed with R (version 2.15.1).
RESULTS
Clinicopathological Features of Patients
Clinicopathological features of patients are reported in table 1. The median age at time of surgery was 64.8± 8.8 years. A full follow-up period was available for all patients with a mean of 38.7 months (ranging from 2 to 118 months). This cohort represents ICC cases encountered in clinical practice, particularly with an even distribution according to the UICC 7ed classification (37.5%, 30 %, 25%, and 7.5% for stage I, II, III, and IV respectively).
Among the 40 patients, a recurrence occurred in about half of cases during the follow-up period. 
The Stroma of ICC Exhibits CSC Gene Signatures
Stromal Expression of EpCAM is an Independent Factor of Prognosis
Univariate and multivariable analyses of risk factors influencing OS and DFS are reported in Tables 2 and 3 non liver tissue, as previously reported [13] . Univariate analysis revealed that the overexpression of CD44 and EpCAM in tumor stroma was associated with worse OS and DFS. Multivariable analysis confirmed that EpCAM overexpression in tumor stroma was an independent risk factor of poor OS and DFS. Interestingly, the marked staining of EpCAM in the surrounding non-tumor fibrous tissue was also significantly associated with a reduced DFS.
In the early 2000s, the concept of CSC role in tumorigenesis and in cell spreading has been emerged [14] . Experimental evidences suggested that HCC and ICC may derive from common hepatic progenitor cells (HPCs) or oval cells [5, 15, 16] . HPCs are located in the smallest and most peripheral branches of the biliary tree; the ductules and the canals of Hering at the interface between the parenchyma and the portal tract mesenchyme [17] . The activation of HPC compartment can give rise to ductular reactions (DR) as a response to liver damage, 13 which is correlated to the degree of inflammation and fibrosis in many chronic liver diseases.
Recently, Cai et al. demonstrated that DR/HPCs activation in non-tumor tissue contribute on the risk of recurrence of hepatocholangiocarcinoma (CHC) after curative resection [18] .
Similarly, Coulouarn et al. showed by a genome-wide transcriptionnal analysis that this particular of mixed tumor exhibits stem/progenitor features associated with poor prognosis [19] .
Several recent reports described a specific niche into the stroma where CSC are located [20, 21] . The Current evidence revealed that the tumor niche has a pivotal role in controlling cancer homeostasis and progression. In ICC, CSCs are supposed to be generated through the genetic alteration of hepatic stem cells (HSCs), HPCs and probably from cholangiocytes themselves [22] . CSCs are identified through the presence of specific cell surface markers.
The most specific currently described CSC biomarkers in cholangiocarcinoma include CD133/prominin-1 [23] , CD44 [24] and EpCAM [25] . Wang EpCAM in HSC and HPC led to a decrease in the invasiveness of HCC cell lines [27] .
Monoclonal antibodies against EpCAM are now available and were demonstrated to be effective in several solid tumors, namely prostatic carcinoma [28] , uterine papillary carcinoma and pancreatic carcinoma [29] . Among the anti-EpCAM antibodies, adecatumumab (MT201)
is a safe promising fully human antibody with a long half-life, well tolerated by patients [30] .
A limitation of the present work is linked to the small size of the study group, and further studies are needed to confirm the results. Furthermore, EpCAM is a surface biomarker of CSC, but also known to be as a marker widely associated with the epithelial to mesenchymal transition which could partly explain its role in ICC aggressiveness.
In conclusion, the present study suggests a potential role of CSC in the aggressiveness and recurrence of ICC. In addition, we propose EpCAM as a new independent risk factor for poorest survival which can be performed in routine immunohistochemistry. Further studies are mandatory to validate EpCAM as a biomarker for adapted therapies of ICC, including surgical resection of the tumor and the follow-up of patients. In fact, patients with high expression of EpCAM might benefit from an adjuvant treatment using a combination of CT regimens and targeted biotherapy, such as the neutralizing antibodies adecatunumab, which is an appealing strategy and to be explored in the near future. 
